Get the Stockscreener App
0.84
0.53%
-0.0045
Jaguar Health Inc stock is traded at $0.84, with a volume of 81,041.
It is down -0.53% in the last 24 hours and down -28.81% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$0.8445
Open:
$0.8284
24h Volume:
81,041
Relative Volume:
0.19
Market Cap:
$11.05M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.0519
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
-5.02%
1M Performance:
-28.81%
6M Performance:
-21.50%
1Y Performance:
-84.39%
1-Day Range:
$0.8214
$0.8468
1-Week Range:
$0.8214
$0.9016
52-Week Range:
$0.7786
$21.60
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.84 | 11.05M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.00 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.08 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.80 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.91 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health to Present at Biotech Showcase 2019 in San Francisco - ACCESS Newswire
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference - Huntsville Item
Breakthrough Plant-Based Drug Takes Aim at $38B ADHD & Schizophrenia Markets - StockTitan
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 30% - Simply Wall St
Jaguar Health extends loan maturity, issues stock for royalty interest reduction - MSN
JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan
Jaguar Health announces first SBS-IF patient dosed in IIT trial of crofelemer - TipRanks
Rare Disease Breakthrough: First SBS-IF Patient Dosed in Groundbreaking Pediatric Trial - StockTitan
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO - ACCESS Newswire
This Drug Could Fix The Biggest Problem With Ozempic and Wegovy - StockTitan
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs - ACCESS Newswire
Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants - ACCESS Newswire
Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer" - ACCESS Newswire
Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea - ACCESS Newswire
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - ACCESS Newswire
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) - ACCESS Newswire
Jaguar Health Stock Hits 52-Week Low at $0.81 Amid Challenges - MSN
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch - ACCESS Newswire
Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming - ACCESS Newswire
Jaguar Health Stock Hits 52-Week Low at $0.81 Amid Challenges By Investing.com - Investing.com South Africa
Jaguar Health Begins Crucial Trial for Rare Disease Drug Crofelemer in UAE Medical Center - StockTitan
Jaguar Health stock hits 52-week low at $0.84 amid challenges - Investing.com Australia
Jaguar Health Awards Strategic RSU Grants to Key New Employees in Retention Push - StockTitan
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Hastings Tribune
Botanical and Plant-Derived Drugs Market to Grow by USD 18.66 Billion (2025-2029), Driven by Government Initiatives and AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase - AccessWire
Jaguar Health CEO to Present at Two Major Healthcare Investor Events in January 2025 - StockTitan
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum - Joplin Globe
Magdalena Biosciences to Submit Groundbreaking IND for First-Ever Schizophrenia Cognitive Treatment - StockTitan
Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Earnings Call Transcript - MSN
FDA approves orphan-drug designation for Jaguar Health’s cholera drug, Crofelemer - MSN
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - Barchart
Jaguar Health's Magdalena JV Imports 6kg of Coca Leaf for Novel Mental Health Drug Development - StockTitan
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder - Corsicana Daily Sun
Jaguar Health Launches Phase 2 Trial for Rare Pediatric Disease Treatment with Orphan Drug Status - StockTitan
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera - Eagle-Tribune
Jaguar Health Secures FDA Orphan Drug Status for Groundbreaking Cholera Treatment - StockTitan
Jaguar Health stock plunges to 52-week low of $0.87 By Investing.com - Investing.com Canada
Jaguar Health stock plunges to 52-week low of $0.87 - Investing.com
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES - Quantisnow
Jaguar Health Advances 5 Clinical Trials for Rare Disease Drug Crofelemer, Unveils Development Roadmap - StockTitan
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer - Yahoo Finance
Jaguar Health's Phase 3 Trial Shows Breakthrough Results for Cancer Therapy Diarrhea Treatment - StockTitan
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) - Corsicana Daily Sun
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):